Phathom Pharmaceuticals, Inc. Revenue Disclosure
To date, our only source of revenue has been from the U.S. sales of VOQUEZNA products, which the Company began selling during the fourth quarter of 2023. The Company records its best estimate of chargebacks, sales discounts and other reserves to which customers are likely expected to be entitled to as contra accounts receivable charges, and within accrued expenses if payable to a third-party or related to product returns on the balance sheets. During the years ended December 31, 2025 and 2024, the Company recognized $175.1 million and $55.3 million, respectively, of net product revenues related to sales of VOQUEZNA, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK.
The following table provides a summary of the Company's revenue allowances and related accruals for the year ended December 31, 2025 which have been deducting in arriving at product revenues, net (in thousands):
|
|
Customer Credits, Discounts and Allowances |
|
|
Rebates, Returns and Co-Pay Assistance |
|
|
|
|
|||
|
|
(contra accounts receivable) |
|
|
(accrued expenses) |
|
|
Total |
|
|||
Balance as of January 1, 2025 |
|
$ |
5,659 |
|
|
$ |
29,987 |
|
|
$ |
35,646 |
|
Accruals |
|
|
65,653 |
|
|
|
174,330 |
|
|
|
239,983 |
|
Utilizations |
|
|
(60,666 |
) |
|
|
(138,855 |
) |
|
|
(199,521 |
) |
Balance as of December 31, 2025 |
|
$ |
10,646 |
|
|
$ |
65,462 |
|
|
$ |
76,108 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 26, 2026 | Showing above |
| 2024 | Mar 6, 2025 | |
| 2023 | Mar 7, 2024 | |
| 2022 | Feb 28, 2023 | |
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.